

- Idiopathic pulmonary fibrosis (IPF), 684-686, 685f, 686b
 - pathogenesis of, 685-686
 - environmental factors, 685
 - genetic factors, 685
- Idiopathic pulmonary hemosiderosis, 701
- α -1-iduronidase, 155
- IFIH1 gene, autoimmune diseases and, 216t
- IgA nephropathy, 910t, 923-924, 923b-925b, 923f
- IgE-coated mast cells, 203
- IL2RA gene, autoimmune diseases and, 216t
- IL23R gene, autoimmune diseases and, 216t
- Immature malignant teratomas, 1030, 1030b, 1030f
- Immediate reaction, after allergen exposure, 201
- Immediate transient response, in inflammation, 74
- Immediate (type I) hypersensitivity, 201-205, 201t, 205b
 - examples of disorders caused by, 204t
 - local, 205
 - mediators of, 203-204
 - phases of, 201f
 - sequence of events in, 202f
- Immune complex(es)
 - deposition of, 207-208
 - formation of, 207
 - pathogenesis of diseases caused by, 208b
 - and tissue injury, 208
- Immune complex-associated vasculitis, 506-507
- Immune complex-mediated (type III) hypersensitivity, 201t, 207-208, 207f
 - examples of, 207t
 - local, 208
 - morphology of, 208b
- Immune destruction, evasion of, in cancer, 316
- Immune dysregulation,
 - Polyendocrinopathy, Enteropathy, X-linked (IPEX), 213-214
- Immune evasion, by microbes, 345-347, 346f, 347b
- Immune granulomas, 97-98
- Immune-privileged sites, 214
- Immune reactions, inflammation due to, 72
- Immune reconstitution inflammatory syndrome, 256
- Immune responses
 - adaptive immunity in, 188-189
 - cell-mediated immunity in, 189, 197-198, 197f, 199b-200b
 - cells of immune system in, 189-193
 - cytokines in, 196
 - decline of, 199-200
 - humoral immunity in, 198-199, 199f
 - lymphocyte activation and, 196-200
 - normal, 186-200, 199b-200b
- Immune surveillance, 310, 312-314, 314b
- Immune system
 - cells of, 189-193
 - diseases of, 185-264
 - evasion of, 313, 313f
 - immunodeficiency syndromes, 237-256
 - messenger molecules of, 196
 - tissues of, 193-194
- Immune system disorder(s)
 - amyloidosis as, 261f, 262b
 - of aging, 260
 - classification of, 259t
 - endocrine, 260
 - hemodialysis-associated, 260
 - heredofamilial, 259-260
 - localized, 260
 - pathogenesis of, 258-262, 258f
 - perivascular, 657
 - plasma cell disorders associated with, 258-259
 - primary, 258-259
 - properties of amyloid proteins and, 257-258
 - reactive systemic, 259
 - vascular, 262
 - autoimmune
 - chronic discoid lupus erythematosus, 225-226
 - mixed connective tissue disease, 231
 - polyarteritis nodosa and other vasculitides, 231
 - systemic sclerosis (scleroderma), 228-230
 - hypersensitivity reactions as inflammation due to, 72
- Immune thrombocytopenia, 658
- Immune thrombocytopenic purpura (ITP), 665b
 - acute, 659
 - chronic, 658-659
 - clinical features of, 658-659
 - morphology of, 658b
 - pathogenesis of, 658
- Immunity
 - adaptive (acquired, specific), 71, 186, 186f
 - defects in, 238
 - peptide display system of, 194-196
 - innate (natural, native), 186
- Immunodeficiency, 236
 - associated with systemic diseases, 242-243
 - common variable, 241-242
 - primary
 - hyper-IgM syndrome, 241
 - isolated IgA deficiency, 242
 - Wiskott-Aldrich syndrome, 242
- Immunodeficiency-associated large B-cell lymphoma, 596
- Immunodeficiency diseases, 200
- Immunoglobulin A (IgA), in humoral immunity, 198-199
- Immunoglobulin E (IgE), 1162
 - in asthma, 680
- Immunoglobulin E (IgE) antibody,
 - production of, 202
- Immunoglobulin G (IgG), in humoral immunity, 198-199
- Immunoglobulin G4 (IgG4)-related disease, 231, 496b-499b
- Immuno-hemolytic anemia, 643-644, 643t, 644b
- Immunohistochemistry, 334
- Immunologic disorder, and systemic lupus erythematosus, 218t
- Immunologic memory, 199-200
- Immunologic reactions, cell injury due to, 39
- Immunologic tolerance, 212-214
 - and autoimmunity, 217b
- Immunologically mediated tissue injury, 200-211
- Immunoregulatory pathways, activation of, in immune evasion, 313
- Immunosuppression-associated Kaposi sarcoma, 519
- Immunosuppressive factors, secretion of, by cancer cells, 313
- Imperforate anus, 750
- Impetigo, 1176-1177, 1177b
- Inactive plaques, in multiple sclerosis, 1284b-1285b
- Inborn errors of metabolism, 464-471, 464t
 - cystic fibrosis as, 466-471, 468f, 470f
 - clinical features of, 470-471, 470t
 - environmental modifiers of, 469-470
 - genetic modifiers of, 469-470
 - morphology of, 469b-470b
 - galactosemia as, 465-466, 465f
 - phenylketonuria as, 464-465, 464f
- Inclusion body myositis, 1240
 - morphology of, 1240b
- Incomplete penetrance, 140
- Indian hedgehog (Ihh), 1182
- Indirect-acting carcinogens, 323-324
- Indirect Coombs antiglobulin test, 643
- Indoor air pollution, 409-410
- Induced pluripotent stem cells (iPS cells), 28-29, 28f
- Inducible nitric oxide synthase (iNOS), 80
- Industrial exposures, 413-417
- Infant mortality rate, 451
- Infants
 - causes of death in, 451, 452t
 - congenital anomalies in, 452-456
 - causes of, 454-456, 454t
 - pathogenesis of, 455-456, 455f
 - diseases of, 451-482
 - fetal hydrops in, 461-463
 - clinical features of, 463
 - immune, 461-462, 461f
 - morphology of, 462b-463b
 - nonimmune, 461t, 462-463, 463f
 - inborn errors of metabolism in, 464-471
 - perinatal infections in, 459-461
 - premature, 456-459
 - necrotizing enterocolitis in, 459, 460f
 - neonatal respiratory distress syndrome in, 457-459, 458f
 - risk factors for, 456
 - sudden infant death syndrome in, 471-473, 472b, 472t
 - tumors and tumor-like lesions in, 473-481
 - benign, 473-475, 474f
 - malignant, 475-481, 475t
- Infarct(s)
 - defined, 129
 - factors that influence development of, 130-131
 - morphology of, 129b-130b
 - red, 129-130, 130f
 - splenic, in sickle cell disease, 636-637, 637f
 - white, 130, 130f
 - of Zahn, 863
- Infarction(s), 129-131, 131b
 - myocardial, 540-549
 - clinical features of, 547, 547f
 - consequences and complications of, 547-549, 548f
 - expansion of, 549
 - extension of, 555
 - incidence and risk factors for, 540
 - pathogenesis of, 540-549
 - patterns of, 543-545, 543f
 - reperfusion of, 545-547, 546f